BioSpace News Archive

The company’s Nomination Committee has decided to present the following proposal to the Annual General Meeting 2018.

Full-Year Net Revenues Increased to $105.9 Million Versus $54.3 Million in Full-Year 2016.

Mr. Tobin currently serves on a number of Boards, including TransMedics, Inc., Oxford Immunotec Global PLC, and Globus Medical, Inc.

Today reported financial results for the full year ended December 31, 2017 and provided a business update.

Announced today financial and operational results for the three and twelve months ended December 31, 2017.

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company (“Advaxis” or the “Company”) focused on the discovery, development and commercialization of cancer immunotherapies, announced today that Company management will present at the following upcoming March 2018 conferences

Kadimastem announced that it has received the approval of the Ministry of Health’s Supreme Committee, for conducting its phase I/IIa clinical trial in ALS patients using the unique cell therapy developed by the company.

Escalier Biosciences BV announced the closing of a $19 million Series B financing.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Universal Flu Vaccine candidate M-001, announced today the signing of a Master Service Agreement (MSA) with a contract research organization (CRO) to conduct the first pivotal, clinical efficacy, Phase 3 trial of M-001.

-- Boehringer Ingelheim and Vanderbilt University collaborate to develop novel anti-cancer drugs that inhibit the MCL1 (myeloid cell leukemia 1) protein -- There are no existing therapies targeting MCL1, which is highly prevalent in many difficult-to-treat cancers -- This is the third collaboration between Boehringer Ingelheim and Vanderbilt University